Key result
Dexrazoxane shows mixed effects on doxorubicin-induced nephrotoxicity, improving histology and creatinine but worsening urea.
Why the study?
Doxorubicin causes critical nephrotoxicity manifested as azotemia in cats, motivating evaluation of whether dexrazoxane and carvedilol can protect against these nephrotoxic effects.
Does dexrazoxane and carvedilol prevent doxorubicin-induced nephrotoxicity in a rat model?
Does dexrazoxane and carvedilol prevent doxorubicin-induced nephrotoxicity in a rat model?
In a rat model of doxorubicin-induced nephrotoxicity, dexrazoxane showed mixed effects by improving histology and creatinine but worsening urea levels, indicating it cannot be unequivocally recommended for preventing DOX nephrotoxicity.
Cannot yet recommend dexrazoxane for doxorubicin nephroprotection; leaves open net renal effects in translational models.
Doxorubicin (DOX) is a cytostatic drug with a broad spectrum of anticancer activity that has been used in oncology for over 50 years. Among many adverse effects in humans, the most dangerous is late dilated cardiomyopathy, which appears even years after completion of therapy. However, in cats, the critical organ for the toxic effects of DOX is the kidney. Herein, nephrotoxicity is manifested as azotemia. The main aim of our study was to evaluate the protective effect of dexrazoxane (DEX) and carvedilol (CVD) against the nephrotoxic effects of DOX. Nephrotoxicity studies were performed in a rat model of repeated DOX administration. Analyzed blood morphological, biochemical and histopathological findings revealed that DEX has a dual effect: it positively impacts DOX-induced histological alterations and creatinine levels while negatively affecting urea concentration. Thus, the results do not support univocally recommend DEX to prevent nephrotoxicity caused by DOX in cats. However, further studies using initially lower doses of DEX are needed to assess the prevention of nephrotoxicity in cats clinically treated with DOX.
No takes yet. Share an insight, caveat, or question.
Szponar et al. (2024) studied Doxorubicin-induced nephrotoxicity (n=100). Dexrazoxane and Carvedilol vs. Doxorubicin alone (1.6 mg/kg) was evaluated on Nephrotoxicity assessed via biochemical markers (creatinine, urea, phosphorus) and histopathological changes. Dexrazoxane positively impacted doxorubicin-induced histological alterations and normalized creatinine levels, but negatively affected urea concentration, indicating mixed effects on nephrotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: